跳至主要内容
临床试验/NCT06281912
NCT06281912尚未招募不适用

Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients

Azienda Ospedaliera di Perugia13 个研究点 分布在 7 个国家目标入组 70 人开始时间: 2024年3月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
70
试验地点
13
主要终点
rate of objective response

研究概览

简要总结

This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or metastatic disease

详细描述

The aim of the study is to evaluate the activity and efficacy of anti PD-1 antibodies in adolescent, childhood and young adult with early and advanced melanomas through a multicenter transnational European retrospective analysis Clinical outcomes will be retrospectively retrieved beginning from the primary diagnosis of melanoma. Clinical outcomes will be retrospectively evaluated starting from the time of start of treatment for up to a the most recent follow-up. Data collected will include demographic information, disease history, baseline conditions, clinical outcomes of interest.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
12 Years 至 30 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients of either sex aged ≥ 12 years;
  • Histologically confirmed melanoma;
  • Anti PD-1 Immunotherapy (Ipilimumab plus Nivolumab);
  • Previous and subsequent treatments will be collected;
  • Clinical and follow-up data available

排除标准

  • No immunotherapy received;
  • No melanoma;
  • Age > 30 yrs

结局指标

主要结局

rate of objective response

时间窗: 12 months

efficay of anti PD-1 antibodies in adolescent, childhood and young through Tumor assessment revision adult with early and advanced melanomas

次要结局

  • adverse event incidence(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mario Mandalà

Associate Professor

Azienda Ospedaliera di Perugia

研究点 (13)

Loading locations...

相似试验